Life sciences M&A optimism resulted in record deal announcements first quarter
Our Global Capital Confidence Barometer shows life sciences expectations continue to be positive, with 50% of executives planning to pursue M&A in the next year.
Life sciences focus on digital strategy and ecosystem
M&A may be quickest way for life sciences companies embracing digital technology to support improved clinical outcomes. Read our Life Sciences Digital Deal Economy 2018 study.
Outcomes-based contracting in life sciences
While many have found outcomes-based contracts a challenge, there is a growing belief that OBC can be a sustainable model for the health care industry.
2018 Global Corporate Divestment Study – Life Sciences
Divesting is a strategic pillar for enhancing life sciences companies’ growth. Read our life sciences divestment study to learn more.
How robotics is reshaping the biopharma value chain
To unlock the full value of robotics process automation, companies must recognize the transformational beneﬁts and limitations.
Life Sciences 4.0: Securing value through data-driven platforms
Life sciences companies must consider how and when to participate in care platforms that can collect and share data in real time.
Choose your deal strategy wisely
We conducted research based on life sciences transactions that closed between 2010 and 2017 to learn whether M&A contributes to shareholder value.
2018 M&A Firepower Report: Life sciences deals and data
M&A remains essential for growth, especially as technology’s health care convergence threatens traditional business models.
Looking beyond China to create a global IVD company
Explore insights from the CEO of Shanghai Kehua Bio-Engineering, an in vitro diagnostics company, on strategies for growth and expansion.

Life Sciences

The need for alignment to achieve health outcomes for all

As populations age and chronic diseases become commonplace, health care will take an ever larger share of GDP. Scientific progress, augmented intelligence and a more empowered patient are driving changes in the delivery of health care to a personalized experience that demands health outcomes as the core metric. This is causing a power shift among traditional stakeholder groups, with new entrants (often not driven by profit) disrupting incumbents.

Innovation, productivity and access to patients remain the industry’s biggest challenges. These trends challenge the capital strategy of every link in the life sciences value chain, from R&D and product supply to product launch and patient-centric operating models.

Our Global Life Sciences Sector brings together a worldwide network of 15,000 sector-focused professionals to anticipate trends, identify their implications and help our clients create competitive advantage. We can help you navigate your way forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

The future of life sciences

EY brings together a global network of 15,000 industry professionals to anticipate trends and strengthen clients’ competitive advantage. Learn more about our life sciences services.

Contact us

Contact a member of our global team.

Connect with us

Stay connected with us through social media, email alerts or webcasts.

The future of life sciences

EY brings together a global network of 15,000 industry professionals to anticipate trends and strengthen clients’ competitive advantage. Learn more about our life sciences services.

Navigating Brexit in life sciences

Life sciences companies weighing their options have a number of opportunities and risks to consider.

EY_LifeSciences